|
WO2021062382A1
|
|
Heterodimeric proteins
|
|
WO2021042019A1
|
|
Anti-cd96 antibodies and methods of use thereof
|
|
WO2021016534A2
|
|
Antigenic polypeptides and methods of use thereof
|
|
WO2021016531A1
|
|
Antigenic polypeptides and methods of use thereof
|
|
WO2019212958A1
|
|
Systems and methods for token-based reimbursement and disbursement
|
|
KR20210005646A
|
|
Heat shock protein-binding peptide composition and method for use thereof
|
|
CN112074535A
|
|
anti-CD 73 antibodies and methods of use thereof
|
|
WO2019046856A1
|
|
T cell receptors that bind to mixed lineage leukemia (mll)-specific phosphopeptides and methods of use thereof
|
|
TW201843178A
|
|
Anti-TIGIT antibodies and methods of use thereof
|
|
TW201841942A
|
|
Anti-CD137 antibodies and methods of use thereof
|
|
AU2018207172A1
|
|
T cell receptors that bind to NY-ESO-1 and methods of use thereof
|
|
BR112019011651A2
|
|
ANTI-CTTLA-4 ANTIBODIES AND METHODS OF USE OF THE SAME
|
|
CA3046082A1
|
|
Antibodies and methods of use thereof
|
|
CA3041340A1
|
|
Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
|
|
CN110023337A
|
|
Anti-lag-3 antibody and its application method
|
|
TW201803903A
|
|
Anti-TIM-3 antibodies and methods of use thereof
|
|
WO2017165416A1
|
|
Protected derivatives of 2-amino-4-phosphobutanoic acid
|
|
EP3383430A1
|
|
Antibodies and methods of use thereof
|
|
EP3383914A1
|
|
Anti-ox40 antibodies and methods of use thereof
|
|
WO2017096276A1
|
|
Anti-gitr antibodies and methods of use thereof
|
